{"id":"W4387135422","doi":"10.1136/ijgc-2023-esgo.44","title":"#1015 Mirvetuximab soravtansine demonstrates longer overall survival and progression-free survival by prior lines of therapy vs chemotherapy in platinum-resistant ovarian cancer and high folate receptor alpha expression in the MIRASOL trial","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Progression-free survival; Hazard ratio; Medicine; Internal medicine; Clinical endpoint; Oncology; Topotecan; Population; Ovarian cancer; Adverse effect; Paclitaxel; Confidence interval; Chemotherapy; Cancer; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009394201,0.0005489534,0.001156779,0.0001332847,0.0002131567,0.0008728773,0.0003280021,0.0006496889,0.003848016],"category_scores_gemma":[0.0009148821,0.0002845451,0.001571818,0.0001635651,0.0003871104,0.0005689638,0.0002712469,0.001568224,0.0005317331],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006160816,"about_ca_system_score_gemma":0.0005328638,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007514159,"about_ca_topic_score_gemma":0.002872812,"domain_scores_codex":[0.9996243,0.0001805971,0.00002941937,0.00006289008,0.00004350432,0.00005934591],"domain_scores_gemma":[0.9995802,0.0001131491,0.0001069236,0.00003666478,0.00002997159,0.000133029],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.899609,0.001800771,0.01096003,0.0006433664,0.006223017,0.0001204749,0.00008952439,0.00106854,0.01135911,0.0004460266,0.003563457,0.06411672],"study_design_scores_gemma":[0.5655422,0.2455561,0.1462354,0.0002829054,0.01251935,0.0005240687,0.0002029245,0.004005887,0.007976977,0.001278218,0.01575302,0.0001231345],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991273,0.003759911,0.0001812647,0.0009236247,0.0003162766,0.0001288217,0.0005234072,0.00004658452,0.002847163],"genre_scores_gemma":[0.9940818,0.001122467,0.0003113812,0.0006990417,0.0001860195,0.0001065329,0.0009851775,0.000015722,0.002491772],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003848016,"threshold_uncertainty_score":0.01287287,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03363870962360981,"score_gpt":0.3423134550101176,"score_spread":0.3086747453865077,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}